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Preclinical modeling of myelodysplastic syndromes
K Rouault-Pierre1,7, SA Mian1,2,7, M Goulard3, A Abarrategi1, A Di Tulio1, AE Smith2,4, A Mohamedali2, S Best2, A-M Nloga5,
AG Kulasekararaj4, L Ades5, C Chomienne3,6, P Fenaux3,5, C Dosquet3,6,8, GJ Mufti2,4,8 and D Bonnet1,8
Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematological clonal disorders. Here, we have tested the
bone marrow (BM) cells from 38 MDS patients covering all risk groups in two immunodeﬁcient mouse models: NSG and NSG-S. Our
data show comparable level of engraftment in both models. The level of engraftment was patient speciﬁc with no correlation to
any speciﬁc MDS risk group. Furthermore, the co-injection of mesenchymal stromal cells (MSCs) did not improve the level of
engraftment. Finally, we have developed an in vitro two-dimensional co-culture system as an alternative tool to in vivo. Using our
in vitro system, we have been able to co-culture CD34+ cells from MDS patient BM on auto- and/or allogeneic MSCs over 4 weeks
with a fold expansion of up to 600 times. More importantly, these expanded cells conserved their MDS clonal architecture as well as
genomic integrity.
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INTRODUCTION
Myelodysplastic syndromes (MDS) are a heterogeneous group of
clonal hematopoietic stem cell disorders with diverse phenotypes,
characterized mainly by ineffective hematopoiesis and bone
marrow (BM) morphological dysplasia.1–3 The phenotypic hetero-
geneity and the highly variable prognosis of MDS patients make it
difﬁcult to classify the disease subtype and predict the survival as
well as likelihood of transformation to leukemia. It is important to
note that one-third of patients with MDS progress to acute myeloid
leukemia, whereas the remaining two-thirds evolve from low-risk to
high-risk disease.
Over the past decade, there has been signiﬁcant progress in
understanding the molecular pathogenesis underlying the MDS4–7
with studies reporting how self-renewing hematopoietic stem
cells continuously acquire somatic aberrations, and although most
of them are passenger mutations, some ‘potent mutations’ can
constitute a reservoir of preleukemic stem cells.8,9 As more genetic
data are gathered, there is an increased need to understand the
tumor’s evolutionary history using both longitudinal genomic
information and preclinical modeling. Moreover, the dynamics of
interactions between subclones, each with their own super-
imposed developmental hierarchy, whether they compete or are
co-dependent upon each other and hence coordinate clonal
evolution, needs to be elucidated. Notably, patient-derived
xenograft models offer the most advanced preclinical opportunity
to capture the complexities of such malignancies.8,9 A number of
different animal models have been proposed but the more
promising to date are the NSG and the NSG-S (humanized with
stem cell factor (SCF), granulocyte-macrophage colony-stimulating
factor (GM-CSF) and interleukin-3 (IL-3)) immunodeﬁcient
mice.10,11
Here, we have used BM cells from 38 MDS patients (low–
intermediate- and high-risk patients) to generate a preclinical
in vivo and in vitro model that can be used to study clonal
evolution and test targeted therapies. We have used NSG and
NSG-S mice to assess engraftment potential of MDS samples.
Furthermore, using high-depth sequencing, we have conﬁrmed
that the MDS clonal population had engrafted in our mice. Finally,
to overcome the limitations of the low recovery of cells following
xenotransplantation, we have developed an in vitro two-
dimensional (2D) co-culture system allowing expansion of MDS
clones. Using next-generation single-nucleotide polymorphism
arrays, we have demonstrated that this in vitro co-culture system
maintains the genomic landscape of MDS disease BM.
MATERIALS AND METHODS
Patients and samples
Patient samples (n=38) were received from King’s College London
Haemato-Oncology Tissue Bank under research ethics protocol (08/
H0906/94) and from Hospital St Louis (France) under ethical approval
IRB00006477, opinion number 13-027. Demographic and clinical char-
acteristics of the studied patients are detailed in Table 1. All patients were
risk stratiﬁed according to IPSS (International Prognostic Scoring System)
categories covering all risk groups: low–intermediate- to high-risk groups
(Table 1). The clinical variables, FAB (French–American–British), WHO
(World Health Organization() subtype and the prognostic risk of all
patients, were ascertained at the time of sample collection. Mutation
proﬁle of the primary patient BM cells was obtained by whole-exome
sequencing or King’s College London myeloid gene-mutation panel
(Supplementary Table S1).
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Xenotransplantation
NOD/SCID/IL2rγ− / − (NSG) mice and NOD/SCID/IL2rγ− / −/IL-3/GM-CSF/
SCF (NSG-S) mice were a kind gift of Dr Leonard Shultz (The Jackson
Laboratory, Bar Harbor, ME, USA). All animal experiments were
performed in accordance to Home Ofﬁce and CRICK guidelines. Before
transplantation, mice received a sublethal dose of radiation (330–
375 cGy) from a cesium-137 source. Direct intra-BM injection was
performed in the tibia or femur with 1 × 105 to 2 × 105 BM CD34+ cells
(with or without mesenchymal stromal cells (MSCs)) or with 1 × 106
CD3+ depleted mononuclear cells (MNCs; with or without MSCs, 1:1
ratio) from patients and/or normal controls. Engraftment was assessed
at the time of killing (12–18 weeks) and the BM (pooled femurs,
tibias, pelvis) was immunophenotyped by the presence of mCD45,
hCD45, hCD33, hCD19 and hCD3 (BD Biosciences, Oxford, UK) cell
populations. Live cells were stained and sorted on hCD45 phenotype
using FACS Aria SORP (BD Biosciences). Sorted cells were washed in
phosphate-buffered saline and harvested in order to later perform
genomic analysis.
Long-term culture-initiating cell (LTC-IC) assay
LTC assays were performed by plating 1 × 103 CD34+ BM cells in duplicate
on irradiated MS-5 murine stromal cells and/or autologous/allogeneic
MSCs using Myelocult H5100 (StemCell Technologies, Vancouver, BC,
Canada) in the presence of cytokines (20 ng/ml SCF, 20 ng/ml IL-3 and
20 ng/ml thrombopoietin (TPO) from PeproTech, London, UK). After
4 weeks, hCD45+ cells were isolated using EasySep Human CD45 Depletion
Kit (StemCell Technologies, cat. no. 18259). Isolated CD45+ cells were
washed in phosphate-buffered saline, counted and then plated into
methylcellulose as mentioned below. The rest of the cells were harvested
and stored as cell pellet for future use for genomic and single-nucleotide
polymorphism assays. Images of LTC were acquired with a Zeiss
(Cambridge, UK) AxioVert 40 CFL microscope using 5 × lens and connected
to Canon (Melville, NY, USA) PowerShot A640 digital camera.
Colony-forming cell
A total of 500 cells from the primary BM CD34+ enriched fraction were
plated in duplicate in 0.5 ml in 24-well plates with MethoCult H4434
(StemCell Technologies). Similarly, 1 × 105 CD45+ cells recovered from LTC
were plated in duplicate in 35 mm dishes in 1 ml of MethoCult H4435
(StemCell Technologies). Assay was performed under hypoxic conditions
(3% O2). After day 14 of culture, the numbers of colonies were scored.
Further information is available in the Supplementary Methods.
RESULTS AND DISCUSSION
Here we have tested the engraftment potential of MDS in NSG
and/or NSG-S immunodeﬁcient mouse models. Initially, we choose
to screen 11 patients in NSG and/or NSG-S mice by injecting
1 × 106 BM patient MNCs (CD3+ depleted) and then treating with
OKT3 before injection as described in previous studies.12 After
18 weeks, engraftment levels based on human CD45+ cells
(hCD45+) harvested from engrafted mice ranged between 0.01
and 15%. Interestingly, no difference was observed in the level of
engraftment between the NSG and NSG-S mice (Figures 1a and b).
Next, we decided to determine whether patient-derived MSCs
can help to improve the engraftment of MDS BM cells in NSG as
well as in NSG-S mice as has been previously suggested.11,13 Our
results obtained from mice that were injected with 1 × 106 patient
MNCs (CD3+ depleted cells) along with 0.5 × 106 MSCs (autologous
or allogeneic) did not show any improvement in engraftment
levels in both mouse models (Figure 1c).
In order to determine whether enrichment of malignant stem/
progenitor cells can improve the engraftment, we isolated the
CD34+ cells from 22 patient BM and injected cells ranging from
1× 105 to 2 × 105 cells into NSG mice (Supplementary Figure S1).
The hCD45+ engraftment levels measured at the time of killing of
mice ranged between 0.01 and 12%. Surprisingly, our data show
that the level of engraftment is patient speciﬁc (Supplementary
Figure S1) and not dependent on the MDS WHO subtype
(Figure 2a). We next tested whether injecting CD34+ along with
autologous or allogeneic MSCs (from healthy BM donors) could
improve the level of engraftment. Therefore, we injected 1–2 × 105
CD34+ cells with or without 1–2 × 105 MSCs (autologous patient
MSCs and normal healthy donor BM MSCs). Interestingly, no
difference was observed in the engraftment of hCD45+ cells
between mice who received CD34+ cells alone or with MSCs
(Figure 2b). As cells were injected intrabone and MSCs have been
previously suggested to provide ‘niche units’11 that helps in
enhancing the engraftment of MDS BM cells, we assessed the level
of engraftment in the injected bone as well as the rest of the
bones (tibia, femurs and pelvis). The level of hCD45+ cells was
similar between all the analyzed bones at week 18 (Figure 2c),
suggesting that engraftment potential of the MDS BM cells might
be independent of the presence of human MSCs.
Table 1. Clinical data for MDS patients used in this study
UPN Sex WHO
diagnosis
Blasts
(%)
Cytogenetics
MDS1 M RCMD 3 47,XY,+8 [20]
MDS2 M RCMD 3 45,XY-7[8]/46,XY[2]
MDS3 F RAEBII 17 46,XX,del(7)(q21q36) [28]/46,XX [2]
MDS4 M RCMD-RS 2 47,XY,del(20)(q11q13),+21[30]
MDS5 M RARS 2 46,XY [20]
MDS6 M MDS/
MPN
8 47,XY,+8 [30]
MDS7 M RCMD 0 46,XY [20]
MDS9 M RARS-T 1 46,XY [20]
MDS13 M RCMD 1 46,XY[7]
MDS14 F RCMD 2 46,XX,del(5)(q13q31),del(20)
(q11q13) [20] /46,XX [10]
MDS17 M RAEBII 11 46,XY,-7,+mar[10]
MDS20 F RCMD-RS 1 46,XX [20]
MDS22 M RCMD 2 46,XY [20]
MDS24 M RAEBI 9 46,XY[20]
MDS25 M RARS 0 46,XY [20]
MDS27 M RCMD-RS 3 46,XY [20]
MDS35 F Del5q 2 46,XX,del(5)(q13q31) [27] / 46,XX [3]
MDS36 M RCMD 0 46,XY [20]
MDS37 M RCMD 1 46,XY [20]
MDS38 M RCMD 3 46,XY [20]
MDS39 F RCMD 2 46,XX[20]
MDS40 M RCMD 2 46,XY [20]
MDS41 M RCMD 2 46,XY [20]
MDS42 F RCMD 3 46,XX [10]
MDS43 M RAEBII 11 46,XY [20]
MDS44 F RAEBII 15 46,XX [20]
MDS45 M RCMD 3 46,XY[20]
MDS46 M RCMD 2 46,XY [20]
MDS47 M RARS 0 46,XY [20]
MDS48 M RARS 3 47,XY,+8[10]/46,XY[10]
MDS49 F RARS 1 46,XX [20]
MDS50 F RAEBII 2.8 48 XX, 20q-, Trisomy-8, Trisomy-11
MDS51 M CMML 1.7 46,XY [20]
MDS52 F RARS 0.1 46 X,i(X)(q13) [10], 46 XX [12]
MDS53 M CMML 0.7 46 XY del 20 q12 [9], 46 XY [3]
MDS54 F RAEBI 7.4 46 XX
MDS55 F RAEBII 8.8 -4, -7 der5, -13, -5
MDS56 M CMML 3.5 46 XY [23]
Abbreviations: CMML, chronic myelomonocytic leukemia; F, female;
M, male; MDS, myelodysplastic syndrome; MDS/MPN, myelodysplastic/
myeloproliferative neoplasm; RAEB, refractory anemia with excess blasts;
RARS, refractory anemia with ringed sideroblasts; RARS-T, refractory
anemia with ring sideroblasts and thrombocytosis; RCMD, refractory
cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia with
multilineage dysplasia and ringed sideroblasts; WHO, World Health
Organization.
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Figure 1. Xenotransplantation of MDS BM MNCs. (a) Schematic representation of intrabone injection in NSG/NSG-S mice with or without
MSCs. (b) hCD45+ engraftment in total mouse BM at the time of killing from NSG and NSG-S mice injected with patient MNCs (patients n= 11;
NSG mice n= 20; NSG-S mice n= 17). hCD45 ⩾ 0.01% in total mouse BM was considered as successful human cell engraftment. (c) hCD45+
engraftment in total mouse BM at the time of killing from NSG and NSG-S mice injected with patient MNCs±MSCs (autologous/allogeneic),
(patients n= 5 (MDS 36, 37, 38, 39 and 49)); MNCs alone NSG mice n= 10; MNCs+MSCs NSG mice n= 10; MNC alone NSG-S mice n= 9; MNCs
+MSCs NSG-S mice n= 9).
Figure 2. Xenotransplantation of MDS BM CD34+ cells. (a) Percentage of hCD45+ engraftment observed in NSG mice injected with CD34+ cells
from various MDS WHO subtypes (patients n= 22; NSG mice n= 74). hCD45 ⩾ 0.01% in total mouse BM was considered as successful human
cell engraftment. (b) hCD45+ engraftment in total mouse BM at the time of killing from NSG mice injected with patient CD34+±MSCs
(autologous/allogeneic) (CD34+ alone n= 35 mice and patients n= 22, CD34++nMSCs n= 6 mice and patients n= 6; CD34++pMSCs n= 12 mice
and patients n= 6). nMSCs, normal healthy donor MSCs, pMSCs, autologous patient MSCs. (c) Comparison of hCD45+ engraftment observed in
injected bone vs noninjected bones from NSG mice transplanted with patient CD34++MSCs (mice n= 10, patients n= 6 (MDS 6, 9, 17, 18, 20
and 27).
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To conﬁrm the nature of the human engrafted cells recovered
from mice, targeted mutational analysis was performed on
xenografted hCD45+ cells (where available). Our sequencing
analysis conﬁrmed the presence of the malignant MDS clone(s) in
all the mice engrafted with human cells (Supplementary Table S2).
Apart from two cases (MDS1 and MDS38), mutant allele burden of
MDS-related gene mutations were maintained (compared with
day 0 patient BM cells) in the xenografts, irrespective of whether
the mice were injected with MNCs or CD34+ cells.
In order to evaluate the kinetics of human MSC (hMSC)
engraftment in vivo, we transduced MSCs from healthy donors
with a bicistronic vector coexpressing green ﬂuorescent protein
(GFP) and luciferase (with a transduction efﬁciency ranging from
80 to 90%) and coinjected them with CD34+ cells isolated from
cord blood (Figure 3a) into either NSG and NSG-S mice (n= 13).
Control mice (n= 4) were injected only with cord blood CD34+
cells. Bioluminescence was assessed at 4, 24 and 48 h after intra-
BM (right femur) injection and then once a week over a period of
4 weeks as well as at 12 weeks (Figures 3b and c). Strikingly, we
were not able to detect any hMSCs by bioluminescence 1 week
after injection. At week 12, we collected injected bones from 13
mice transplanted with MSC+CD34+ cells and performed immu-
noﬂuorescence staining against the GFP+ protein expressed by
our transduced hMSCs. Although we could not detect hMSCs by
bioluminescence, we observed a few GFP+ cells scattered in the
long injected bone in 2/13 mice (Supplementary Figure S2). We
therefore analyzed the adjacent noninjected bone (right tibia) and
looked for GFP+ cells. Notably, we were not able to detect any
GFP+ cells in the tibia from the two mice that had residual GFP+
cells in injected femur, thereby conﬁrming that MSCs do not have
colonization capacity (Supplementary Figure S3). Next, we sought
to determine whether the level of cord blood CD34+ engraftment
would increase by the coinjection of hMSCs. Interestingly, the
percentage of human cell engraftment was similar in mice that
received CD34+ alone versus CD34++hMSCs (hCD45 45%±24
versus 48%± 35 respectively; (Figure 3c and Supplementary Table
S3). Taken together, these results suggest that hMSCs even
injected intrabone do not persist for 41 week in NSG or NSG-S
mice, and thus potentially explain why their coinjection with
patient MNCs or CD34+ cells do not affect the long-term
engraftment of these cells. However, it is possible that the hMSCs
might be providing a supportive niche during the initial
establishment of the graft as has been suggested by Meydouf
et al.11 (ﬁrst week post transplant) and this effect, if any, subsides
over time (killed 12–18 weeks post injection; Figures 2b and 3c
and Supplementary Table S3).
Our study and other previously published reports have shown
that it is possible to engraft MDS patient samples into
immunodeﬁcient mice, and characterize the nature of the MDS-
initiating cells as well as clonal evolution overtime;8–10 however,
the low level of engraftment generally observed makes these
models impractical to use reliably for screening of potential novel
targeted therapies. Therefore, we focused our attention on
developing an ex vivo 2D culture model. We used autologous
(and/or allogeneic) MSCs and CD34+ cells isolated from patients
BM, therefore providing a unique system to study both the stroma
and hematopoietic cells.
Patients (n= 9) from all WHO MDS subtypes (RARS (refractory
anemia with ringed sideroblasts), RCMD (refractory cytopenia with
multilineage dysplasia), RAEB1 (refractory anemia with excess
blasts-1) and RAEB-2 (refractory anemia with excess blasts-2)) were
chosen for analysis using our 2D co-culture system. Initially, fresh
patient BM CD34− cells were used to expand the MSCs, whereas
part of the CD34+ fraction was used for single-cell clonogenic CFC
assay (Supplementary Figure S4a). Later on, once MSC cultures
were established, MDS patient CD34+ cells were used to generate
LTC-ICs on autologous or allogeneic MSCs.
First, it is important to note that the MDS clone as determined
by the presence of the gene mutation(s) (where available) was
maintained between day 0 and after 4 weeks of culture (Figure 4a
and Supplementary Table S4). Furthermore, although the clonality
was not altered, the cell fold expansion observed was substantial
Figure 3. Xenotransplantation of cord blood (CB) CD34+ cells and tracking of hMSCs. (a) Schematic representation of lentiviral transduction of
human MSCs with GFP–luciferase vector, followed by intrabone injection in NSG/NSG-S mice and in vivo imaging. (b) Bioluminescence plot
showing the photons emitted from luciferase-expressing MSCs over the 12-week period (CD34++MSCs in NSG n= 8; CD34+ alone in NSG n= 2;
CD34++MSCs NSG-S n= 5; CD34+ alone NSG-S n= 2). (c) hCD45+ engraftment in total mouse BM at the time of killing from NSG and NSG-S
mice injected with cord blood CD34+±MSCs (CB CD34++MSCs, NSG= 8, NSG-S= 5; CB CD34+, NSG/NSG-S= 4).
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(ranging from 50 to more than 600 times), now making it feasible
to use multiple approaches/techniques usually limited by the
small number of available cells (Figure 5a and Supplementary
Table S5). It is worth noting that MSCs recovered from RAEB
patients were nonsupportive as indicated by the low hCD45+ cell
expansion. Therefore, we decided to determine whether murine
stroma cell line MS5 could be used as an alternative to hMSC
stromal support for RAEB cases where we observed poor recovery
of hMSCs, as has also been previously reported.14 We observed a
substantial increase in the expansion of CD34+ cells from RAEB
patients. Notably, patient CD34+ cells grown on mouse stroma
now exhibited a similar fold expansion as was observed in MSC
stroma for RARS as well as RCMD patients (Figure 5a).
Next, we investigated the potential of LTC expanded MDS cells
to form long-term culture-initiating cells; bearing in mind that the
impressive cell fold expansion observed on stroma could have
caused an exhaustion of the more primitive malignant cells
(Figure 5a). Both MDS culture on MSCs and on MS5 were able to
give rise to colonies (Figure 5b) with a ratio of burst forming unit-
erythroid/colony forming unit-granulocyte-macrophage (BFU-E/
CFU-GM) colonies similar to that observed at day 0 (Figure 5c).
Finally, we wanted to determine whether 4 weeks of expansion on
a monolayer of stroma cells would have induced any additional
chromosomal instability within the MDS patient cells. Therefore,
we performed single-nucleotide polymorphism karyotyping
(Affymetrix GeneChip System) on pre- and post-LTC-ICs for 3
patients. Our data showed that the clones were stable during the
co-culture and did not induce any additional chromosomal
abnormalities. Importantly, in one patient (MDS48) a minor clone
(o25%) carrying trisomy-8 was also maintained in hCD45+ cells
recovered from the MS5 stroma conditions (Figure 4b and
Supplementary Figure S5). Our data clearly demonstrates that
this 2D in vitro system can be used with a small number of CD34+
cells (often observed) as a surrogate model to study the
therapeutic strategies as well as the potential mechanisms of
drug resistance observed often in MDS patients.
In this report, we used MNCs or CD34+ primary MDS cells and
autologous/allogeneic hMSCs injected intra-BM into different
immunodeﬁcient mouse models. Our results showed that
although it is possible to xenotransplant MDS patient cells, the
engraftment remains low, with or without the coinjection of MSCs,
therefore compromising the test of new therapeutic strategies
in vivo. We showed that human MSCs do not last more than a
week in the mouse BM, therefore suggesting that other
transplantation methods like the use of a three-dimensional
scaffold that others and we have recently reported using acute
myeloid leukemia primary samples15,16 could be of potential use
to better dissect the role if any of MSCs in supporting the MDS
clones. Although the development of preclinical in vivo models is
necessary, we have demonstrated the potential value of the 2D
Figure 4. Sequencing and single-nucleotide polymorphism (SNP) karyotyping of in vitro MDS samples. (a) Mutational analysis of day 0 BM total
nucleated cells or CD34+ cells and hCD45+ cells retrieved after LTC (MSCs and/or MS5; patients n= 6; ‘-’ not available). (b) SNP karyotyping
showing the maintenance of MDS48 clonality between pre- and post-culture. Presence of a trisomy-8 subclone (see red arrow) in both day 0
and post culture on MS-5.
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co-culture system using MSCs (or murine MS5) as an alternative
model to study MDS. This ex vivo culture system, which lasts for
only 4 weeks and requires low number of human CD34+ cells,
provides a robust preclinical assessment model to test therapeutic
effects of different drugs and other approaches on the MDS
clonality before treatment of MDS patients as well as provides a
model to better dissect the cross-talk between MSCs and the
malignant clones.
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